Johnson & Johnson (NYSE:JNJ) fell ~3% in early trading on Wednesday, marking its biggest intraday drop since July 2023, even as the healthcare giant posted better-than-expected financials for Q4 ...

J&J said that about a third of adults will not respond to oral antidepressants alone. Sign up here to get The Results Are In with Dr. Sanjay Gupta every Friday from the CNN Health team.

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023. It has made several transactions in the past few years to boost its ...

J&J's $132 per-share offer implies 39% premium Deal could kick off spree of activity in sector in 2025 CEO says such large deals not common The deal would help accelerate growth in J&J's drugs ...